A Green Sign – Lifestyle

Author: Sanofi Winthrop Industrie

Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

March 30, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

March 27, 2026
Press release: Availability of the Q1 2026 aide-mémoire

March 24, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

March 24, 2026
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

March 18, 2026
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

March 6, 2026
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report

March 6, 2026
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

March 5, 2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

March 5, 2026
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

March 5, 2026